Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIMECO: Islet Transplantation vs Intensive Insulin in Type 1 Diabetes
NCT01148680Phase 3Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Jun 2010
- Primary completion
- Aug 2018
- Modality
- Cell Therapies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of allogeneic pancreatic islets in type 1 diabetes mellitus (T1D) (2 arms), sponsored by CHU Grenoble Alpes. Primary endpoint: Beta Score Evaluation at 6 months. Started Jun 2010; status: completed.
02
Drugs
allogeneic pancreatic islets
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01148680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01148680.